LOG IN
SIGN UP
MARKET
CRDF
CRDF
Cardiff Oncology Inc
NASDAQ
1.630
+0.050
+3.16%
After Hours: 1.700 +0.07 +4.29% 19:58 06/02 EDT
OPEN
1.610
PREV CLOSE
1.580
HIGH
1.630
LOW
1.560
VOLUME
136.46K
TURNOVER
0
52 WEEK HIGH
3.410
52 WEEK LOW
1.200
MARKET CAP
72.82M
P/E (TTM)
-1.8397
1D
5D
1M
3M
1Y
5Y
A Look At Cardiff: The PLK1 Onco Play With Not Much Runway Left
Seeking Alpha · 4d ago
HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Lowers Price Target to $14
Benzinga · 05/09 11:04
--HC Wainwright Trims Cardiff Oncology Price Target to $14 From $15, Maintains Buy Rating
--HC Wainwright Trims Cardiff Oncology Price Target to $14 From $15, Maintains Buy Rating
MT Newswires · 05/09 08:16
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 05/04 22:25
Cardiff Oncology GAAP EPS of -$0.25 misses by $0.02, revenue of $0.08M beats by $0.02M
Seeking Alpha · 05/04 21:41
BRIEF-Cardiff Oncology Reports First-Quarter 2023 Results And Provides Business Update
Reuters · 05/04 21:15
Cardiff Oncology Q1 EPS $(0.25) Misses $(0.23) Estimate, Sales $83.00K Beat $60.00K Estimate
Benzinga · 05/04 21:07
Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update
PR Newswire · 05/04 20:10
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies across a range of cancers with unmet medical needs. The Company is focused on tumor vulnerabilities with treatment combinations of onvansertib, its selective PLK1 inhibitor, and standard of care (SoC) therapeutics. The Company has five ongoing clinical trials of onvansertib, including two trials (TROV-054 and ONSEMBLE) in second-line treatment in patients with KRAS-mutated Metastatic Colorectal Cancer (mCRC), one trial in second-line treatment in patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), and two investigator-initiated trials in patients with unresectable locally advanced or metastatic Triple Negative Breast Cancer (TNBC) and relapsed Small Cell Lung Cancer (SCLC). The Company has third-party manufacturers and distributors to supply and distribute onvansertib used in its clinical studies and nonclinical development programs.
Webull offers kinds of Cardiff Oncology Inc stock information, including NASDAQ:CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.